Blasco J M, Gamazo C, Winter A J, Jiménez de Bagüés M P, Marín C, Barberán M, Moriyón I, Alonso-Urmeneta B, Díaz R
Servicio de Investigación Agraria, Diputación General de Aragón, Zaragoza, Spain.
Vet Immunol Immunopathol. 1993 Aug;37(3-4):257-70. doi: 10.1016/0165-2427(93)90198-d.
Five antigen preparations from Brucella ovis strain REO 198 were incorporated with the pluronic polymer L-121 and muramyl dipeptide and tested as vaccines against B. ovis infection of rams. The antigenic preparations were: (1) a fraction enriched in outer membrane proteins and rough lipopolysaccharide (hot saline extract, HS); (2) the proteins from HS substantially free of lipopolysaccharide; (3) outer membrane blebs; (4) outer membrane-peptidoglycan complexes extracted with detergent; (5) killed whole cells. The experimental vaccines were compared with two standard vaccines, rough Brucella abortus 45/20 whole killed cells in an oil based adjuvant, and live Brucella melitensis Rev 1. Immunizations with non-living vaccines were performed on two occasions, 18 weeks apart. The rams were challenged with a virulent strain of B. ovis 31 weeks after the second vaccination and slaughtered 15 weeks thereafter. Rates of infection in groups vaccinated with Rev 1 (33%), and HS (40%) were significantly lower (P < 0.005 and P < 0.025, respectively) than that in the non-vaccinated control group (87%). Strain 45/20 was the only other vaccine that conferred a significant level of protection (50%) (P < 0.05). The organ distribution of the infection and the level of colonization of infected organs did not differ significantly between infected animals in the various vaccine groups and those in the unvaccinated control group. No statistically significant relationship was detected between the magnitude of the antibody responses to the HS extract, to outer membrane proteins, or to the rough lipopolysaccharide, and freedom from infection. The results indicate that the HS extract of B. ovis may represent a useful alternative to B. melitensis Rev 1 or B. abortus 45/20 as a vaccine against B. ovis.
将绵羊种布鲁氏菌REO 198株的五种抗原制剂与普朗尼克聚合物L-121和胞壁酰二肽混合,并作为疫苗用于测试其对绵羊种布鲁氏菌感染公羊的预防效果。这些抗原制剂分别为:(1) 富含外膜蛋白和粗糙脂多糖的组分(热盐水提取物,HS);(2) 基本不含脂多糖的HS蛋白;(3) 外膜泡;(4) 用去污剂提取的外膜-肽聚糖复合物;(5) 灭活全菌。将这些实验性疫苗与两种标准疫苗进行比较,即油佐剂中的粗糙型流产布鲁氏菌45/20全菌灭活疫苗,以及活的羊种布鲁氏菌Rev 1疫苗。使用非活性疫苗进行两次免疫,间隔18周。在第二次接种疫苗31周后,用强毒株绵羊种布鲁氏菌对公羊进行攻毒,攻毒后15周宰杀。接种Rev 1疫苗组(33%)和HS疫苗组(40%)的感染率显著低于未接种疫苗的对照组(87%)(P分别<0.005和P<0.025)。45/20菌株是唯一一种能提供显著保护水平(50%)的其他疫苗(P<0.05)。在不同疫苗组的感染动物与未接种疫苗的对照组动物之间,感染的器官分布和感染器官的定植水平没有显著差异。在对HS提取物、外膜蛋白或粗糙脂多糖的抗体反应强度与无感染之间,未检测到统计学上的显著关系。结果表明,绵羊种布鲁氏菌的HS提取物可能是一种有用的疫苗,可替代羊种布鲁氏菌Rev 1或流产布鲁氏菌45/20用于预防绵羊种布鲁氏菌感染。